The new strategy, announced on Wednesday by the head of the UK’s drug regulator MHRA, means that the interval between doses can be extended to 12 weeks instead of the previously set three weeks. The British Medical Association (BMA), an organization representing doctors in the UK, has encouraged discussion among …
Read More »